



Prognostic factors and outcome of patients hospitalized with community acquired Pneumonia

Ronak Benisy¹, Zhinous Bayatmakoo*², Haedeh Mobaiyen³

¹ School of Medicine, Tabriz Branch, Islamic Azad University, Tabriz, Iran

² Infectious and Tropical Diseases Research Center, Tabriz University of Medical Sciences, Tabriz, Iran

³ Department of Microbiology, School of Medicine, Tabriz Branch, Islamic Azad University, Tabriz, Iran

Article info

Article History:

Received: 21 Feb. 2018

Accepted: 26 Feb. 2018

ePublished: 10 June 2018

Keywords:

Community-Acquired Infections,
Prognostic Factors,
Mortality,
Prognosis

Abstract

Introduction: Community acquired Pneumonia (CAP) is a common respiratory disease and a common health problem that causes many deaths annually and has burden of costs on health care system. Prognostic factors can be used for assessing and treating patients with CAP. The aim of the present study was to evaluate prognostic factors and outcome of patients hospitalized with CAP in infectious diseases centers.

Methods: In a retrospective-descriptive study, 236 patients with CAP who referred to Imam-Reza and Sina hospitals of Tabriz University of Medical Sciences, Tabriz, Iran, during 2011-2013, were studied. Age, sex, comorbidities, rate of mortality, and laboratory results of patients were evaluated. P value considered statistically significant when ≤ 0.05 for statistical analysis.

Results: The mean age of patients was 68.7 ± 18.9 years, and male to female ratio was 1 to 1.02. The mean duration of hospitalization was 8.0 ± 4.6 days and mortality rate of patients was 11.9%. Increase in heart rate ($r = 0.406$, $P = 0.001$), and respiratory rate of patients ($r = 0.154$, $P = 0.018$), pleural effusion ($r = 0.313$, $P = 0.001$), increase in blood urea level ($r = 0.271$, $P = 0.001$), and increase in creatinine level ($r = 0.226$, $P = 0.001$), had significant correlation with mortality rate of patients.

Conclusion: Based on the findings of the present study, heart rate, respiratory rate, pleural effusion, blood urea level, and creatinine level had significant correlation with mortality rate of patients with CAP. Lung disease, heart disease, and diabetes were the most common comorbid conditions in these patients.

Citation: Benisy R, Bayatmakoo Z, Mobaiyen H. **Prognostic factors and outcome of patients hospitalized with community acquired Pneumonia.** J Anal Res Clin Med 2018; 6(2): 86-92. Doi: 10.15171/jarcm.2018.013

Introduction

Community acquired Pneumonia (CAP) is defined as lung infection acquired from community. Despite advances in diagnosis and treatment of Pneumonia, it is still considered as an important mortality and morbidity factor.¹⁻³

Annually, in the United States (US), average of 5 to 6 million people are infected by CAP, and more than 1 million of them require hospitalization. About 10%-20% of patients with CAP need hospitalization in intensive care unit (ICU), and about 20%-50%

of them finally die.^{5,6} Prevalence of this disease has been estimated as 14 cases per 1000 people annually.⁷

The most prevalence of CAP is in children under 5 years old and elderly people over 75 years old. The prevalence of this disease could be 5 times higher in developing countries compared with developed countries.⁸ In the US, economic burden of CAP has been reported as 17 milliard dollars, and also in the developed countries more than half of the CAP hospitalizations happen in people over 65 years old, and oldness is

* Corresponding Author: Zhinous Bayatmakoo, Email: zhinous_b@yahoo.com



one of the main reasons of mortality and morbidity in this disease.⁹⁻¹¹ Some risk factors have been mentioned such as age over sixty, alcoholism, cardiac diseases, other comorbid lung diseases, immunosuppressive therapies,¹² smoking,¹³ history of Pneumonia and previous respiratory infection, low body mass index (BMI),¹⁴ asthma, and diabetes mellitus (DM).¹⁵ In diagnosing of the disease, clinical symptoms as well as radiographic evidence of lung and leukocytosis are important.¹⁶ In old people symptoms are non-specific.¹⁷⁻¹⁹ While the disease is diagnosed, empirical treatment should be immediately implemented.^{20,21} Delay more than 4 hours in initiating therapy increases risk of mortality.²² Treatment duration changes between 7 to 21 days based on severity of disease and probable pathogen.²³⁻²⁵ In old patients with comorbidity, longer treatment takes place.^{26,27} Using pneumococcal vaccine has been advised in specific conditions, since 95% of Pneumonias are resulted from streptococcus pneumonia. Considering improvements in production of vaccine,²⁸ and efforts in reducing smoking,²⁹ now this microorganism is the cause of 10%-15% of CAP outpatients.³⁰ Of course various bacterial, viral, and fungal factors could be the cause of CAP. In determining disease severity, different scales such as Pneumonia Severity Index (PSI) are used.^{11,21,31} CURB-65 is other scale which is used, and mortality with tachypnea, diastolic pressure under 60 mmHg, and urea over 7 mmol/l are independent factors related to mortality in CAP.^{32,33} This association has not been approved in other studies.³⁴ In our study, independent prognostic factors associated with mortality included pleuritic chest pain, changes in the level of consciousness, vital signs, and neoplastic diseases. In a study conducted in Spain, pulmonary infiltration in the first 48 hours has been reported as bad prognostic factor.³⁵

Considering high prevalence of CAP and importance of mortality prognostic factors, and for reducing health and mortality costs of this disease, the current study has been

conducted in infectious centers of Tabriz University of Medical Sciences, Tabriz, Iran, in order to investigate patients with CAP, prognostic factors, and their clinical outcomes.

Methods

In a descriptive-analytical study, 236 patients with CAP diagnosis, hospitalized in infectious centers of Tabriz University of Medical Sciences during two years of 2012-2013, were randomly chosen based on file numbers and included into the study. Inclusion criteria were: existence of acute respiratory symptoms (fever, cough, sputum, shortness of breath), existence of physical findings (tachycardia, tachypnea, dullness in percussion, consolidation evidence, and crackles), and existence of radiologic findings in chest radiography.

Exclusion criteria were: similar situations that arise in the differential diagnosis (thromboembolism, pulmonary edema, heart failure (HF), chronic Pneumonia), and inadequate information. Questionnaire was completed for all patients based on their file information including demographic information (age, sex, history of stay in sanitarium, smoking, alcohol use, drugs use), comorbidities, recent antibiotic therapy, laboratory parameters such as arterial blood gas (ABG), urea, creatinine, white blood cell (WBC) count, sodium, hematocrit, blood culture results, and other sterile areas), graphic findings of chest, length of stay, and final result of the disease. After collecting primary information, data were finally processed in SPSS software (version 12, SPSS Inc., Chicago, IL, USA) and underwent statistical analysis. Obtained information was presented as mean \pm standard deviation (SD), frequency, and percentage. In order to compare qualitative variables, chi-square test has been used, and to compare quantitative variables independent t-test was applied. To investigate correlation between variables, Pearson coefficient (r) was calculated. In all steps of study, results were considered statistically significant when $P \leq 0.05$.

Table 1. Comparison of laboratory findings in dead and discharged patients with community acquired Pneumonia (CAP) hospitalized in infectious centers of Tabriz University of Medical Sciences, 2012-2013

Test parameter	Patients	Discharged	Passed away	P
Urea (mean ± SD)		31.68 ± 2.19	47.41 ± 8.95	0.001
Serum creatinine (mean ± SD)		1.33 ± 0.38	2.13 ± 1.56	0.004
Sodium (mean ± SD)		134.65 ± 3.62	129.96 ± 3.33	0.001
pH (mean ± SD)		7.38 ± 0.04	7.38 ± 0.06	0.246
Hematocrit (mean ± SD)		40.45 ± 4.10	34.16 ± 3.57	0.001
WBC (mean ± SD)		12117.75 ± 3422.81	10739.28 ± 5179.25	0.001
PCO ₂ (mean ± SD)		38.94 ± 7.42	34.14 ± 5.69	0.001

SD: Standard deviation; WBC: White blood cell; PCO₂: Partial pressure of carbon dioxide

Results

Of 236 investigated patients, 117 patients (49.6%) were men, while 119 patients (50.2%) were women. Mean age of the patients was 68.7 ± 18.9 years. There was no significant difference between men and women in terms of developing CAP (P = 0.660). Of 236 patients, 171 cases (72.5%) were smokers, and mean cigarette consumption was annually 23.73 ± 11.97 pockets. Only 8 patients (3.4%) had history of alcohol drinking and 20 patients (8.5%) had addiction or history of addiction.

Table 1 shows the comparison of laboratory findings in dead and discharged patients. Table 2 shows the correlation of investigated variables with mortality increase. Table 3 shows the relationship between hospitalization days and sex, and the final results of the patients.

Table 2. Correlation (r) of investigated variables with mortality increase in patients with community acquired Pneumonia (CAP) hospitalized in infectious centers of Tabriz University of Medical Sciences, 2012-2013

Statistical parameter Investigated variable	Correlation coefficient (r)	P
Blood urea increase	0.271	0.001
Blood creatinine level increase	0.226	0.001
WBC decrease	0.124	0.058
Respiratory rate increase	0.154	0.018
Heart rate increase	0.406	0.001
Body temperature decrease	0.064	0.331
Pleural effusion	0.313	.001
Incomplete antibiotic therapy	0.103	0.113

WBC: White blood cell

In terms of relationship with comorbid diseases, 23 patients (9.7%) had history of loss of consciousness, 64 patients (27.1%) had comorbid cardiac disease except congestive

HF (CHF), 12 patients (5.1%) had renal problems, 4 patients (1.7%) had liver disease, 57 patients (24.2%) had aspiration history, 86 patients (36.4%) had lung disease, and 23 patients (9.7%) had previous Pneumonia history. In this study, final results of the patients had no significant relationship with systolic blood pressure (P = 0.501, r = 0.035) and with diastolic blood pressure (P = 0.208, r = 0.082).

Table 3. The relationship between hospitalization days and sex, and final results of the patients with community acquired Pneumonia (CAP) hospitalized in infectious centers of Tabriz University of Medical Sciences, 2012-2013

Variables	Hospitalization (day) (mean ± SD)	P
Gender	Male	8.35 ± 4.83
	Female	7.71 ± 4.50
Outcome	Discharge	8.10 ± 4.54
	Death	7.50 ± 5.62

Discussion

Despite developments in diagnosis and treatment of CAP, it is still considered as an important mortality and morbidity factor in the world; and in spite of various studies in the this field, some prognostic factors of CAP are not still identified and reported.³⁵ Based on the current study, 236 patients with CAP were randomly included into a descriptive-retrospective study. Male to female ratio was approximately 1 (1 to 1.02), and mean age was 68.7 ± 18.9 years. Of samples, 72.5% were smokers, 3.4% had alcohol consumption history, and 8.5% had history of addiction. About comorbid diseases, the most prevalent one was history of lung diseases with 36.4% followed by heart diseases (27.1%), and DM

(24.2%). In radiographic study, there was pleural effusion in 24.2%, and also 36.4% had undergone incomplete antibiotic therapy. 9.7% of patients were hospitalized in ICU, and mortality rate was 11.9%. While investigating the relationship between prognostic factors and mortality rate of patients, it was found that increase in heart rate ($r = 0.406$), pleural effusion ($r = 0.313$), increase in blood urea level ($r = 0.271$), and increase in blood creatinine level ($r = 0.226$) were respectively effective factors in mortality rate of patients, and were statistically significant ($P < 0.050$). However, there was a relationship between previous history of incomplete antibiotic therapy and decrease in WBC number in one hand and mortality rate of patients on the other hand; this relationship was not statistically significant ($P > 0.05$).

In a study, Vila-Corcoles et al. investigated 11241 old people, aiming at investigating incidence, etiology, and clinical symptoms of patients with CAP. Duration of this cohort study was 40 months, and research sample was selected from 8 centers in Spain. 44.5% of the patients were men and 55.5% were women. The most comorbidity was DM (23.6%) followed by chronic cardiac diseases and chronic lung diseases. Results of the study showed that mean prevalence of CAP in people with normal immune system was 11.6 in 1000 persons, and that of people with a weakened immune system was 30.9 per 1000 people. The highest prevalence was for patients with chronic lung disease with 46.5 per 1000 people as well as patients with long-term treatment with corticosteroids with 40.1 per 1000 people. In etiology section of 358 studied patients, 131 patients showed diagnosable organism, where streptococcus has been the most prevalent agent organism. Mean hospitalization days of the patients was 10.4 days. 6.3% of the patients had pleural effusion and 2.5% had multi-lobar Pneumonia. Finally, having history of hospitalization due to CAP during the last 2 years, having chronic lung diseases, chronic cardiac and liver diseases, cancer, and

corticosteroid treatments as well as age and male gender were reported as risk factors.⁷

Further, in this study, the number of men and women was approximately the same (1 to 1.02). Mean days of hospitalization of the patients was 8.0 ± 4.6 days. Comorbidity of DM in this study was 24.2%, but the most prevalent comorbidity in the patients was lung diseases (36.4%). Considering retrospective nature of the study and problems related to isolation of organisms, investigating etiological factors was not completely possible and information registered in files of the patients was not complete in this regard.

In this field, Song et al. also conducted a study aiming at investigating epidemiology of CAP comorbid diseases. In this study, 955 patients from 8 Asian countries were studied. Results of the study showed that bronchopulmonary diseases (29.0%) are the most prevalent comorbid disease followed by cardiovascular diseases (CVDs) (19.9%), malignancies (11.7%), and neurological diseases (8.2%). Mortality rate has been reported as 7.3% and the most important statistically significant factors associated with mortality were: stay in a nursing home, mechanical ventilation and malignancies, CVDs, and respiratory rate over 30 per minute.³⁶ In addition, in the present study comorbid lung diseases were the most prevalent comorbidity in the patients (36.4%) followed by cardiac diseases (27.1%). Moreover, based on the results of the current study, increase in creatinine level, respiratory rate, heart rate, and pleural effusion were statistically significant factors associated with increase in mortality rate of the patients. Finally, the mortality rate in this study was 11.9%.

Results of the study by Welte and Kohnlein, aiming at epidemiological investigation of CAP, showed that the mortality rate in outpatients is low (less than two percent), but this rate in patients hospitalized in ICU is more than 50%. Of important risk factors associated with mortality were: age over 65, male sex,

existence of comorbidities such as chronic heart diseases (CHDs), advanced chronic obstructive pulmonary diseases (COPDs), neurological diseases, and cirrhosis of the liver. Stay in nursing home and other care centers was also presented as one of the major causes of acquiring respiratory resistant infections.³⁷

Fujiki et al. also conducted a study in Japan with the purpose of investigating mortality risk factors in patients with CAP. During this study, 208 hospitalized patients with CAP were studied. Results of this study showed that aspiration risk, low systolic blood pressure, advanced cardiac failure, and high Pneumonia score are of mortality-related risk factors in these patients.³⁸

In a prospective study by Garbino et al., with the goal of epidemiological investigation of Pneumonia, 318 adult patients with CAP hospitalized in 7 medical centers were studied during two winters. Mean age of the patients was 70.4 years. Results of the study showed that in spite of high age, mortality rate has been only 8%, and underlying diseases in the patients included HF (23%), COPD (20%), renal failure (15%), and diabetes (12%).³⁹

Conclusion

According to the results obtained, increase in heart rate ($r = 0.406$), pleural effusion ($r = 0.313$), blood urea level ($r = 0.271$),

creatinine level ($r = 0.226$), and respiratory rate of patients ($r = 0.154$) had significant correlation with CAP-related mortality rate of patients. Lung disease, heart disease, and diabetes were the most common comorbid conditions in patients with CAP.

Acknowledgments

This work was supported fully by Infectious and Tropical Diseases Research Center, Tabriz University of Medical Sciences. This is a report of a database from thesis of MSc Ronak Benisi entitled "Prognostic factors and outcome of patients hospitalized with community acquired pneumonia".

Authors' Contribution

All of the authors contributed equally.

Funding

This research was supported by Infectious and Tropical Diseases Research Center, Tabriz University of Medical Sciences.

Conflict of Interest

Authors have no conflict of interest.

Ethical Approval

This study was approved by the Regional Medical Ethics Committee of Tabriz Branch, Islamic Azad University of Medical Sciences, under the number 10210101912019.

References

1. File TM. Community-acquired pneumonia. *Lancet* 2003; 362(9400): 1991-2001. DOI: 10.1016/S0140-6736(03)15021-0
2. Musher DM, Thorner AR. Community-acquired pneumonia. *N Engl J Med* 2014; 371(17): 1619-28. DOI: 10.1056/NEJMra1312885
3. Siber GR, Klugman KP, Makela PH. Pneumococcal vaccines: the impact of conjugate vaccine. Washington, DC: American Society for Microbiology (ASM); 2008.
4. Niederman MS, Mandell LA, Anzueto A, Bass JB, Broughton WA, Campbell GD, et al. Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention. *Am J Respir Crit Care Med* 2001; 163(7): 1730-54. DOI: 10.1164/ajrccm.163.7.at1010
5. Fine MJ, Smith MA, Carson CA, Mutha SS, Sankey SS, Weissfeld LA, et al. Prognosis and outcomes of patients with community-acquired pneumonia. A meta-analysis. *JAMA* 1996; 275(2): 134-41.
6. Kaplan V, Angus DC, Griffin MF, Clermont G, Scott WR, Linde-Zwirble WT. Hospitalized community-acquired pneumonia in the elderly: Age- and sex-related patterns of care and outcome in the United States. *Am J Respir Crit Care Med* 2002; 165(6): 766-72. DOI: 10.1164/ajrccm.165.6.2103038
7. Vila-Corcoles A, Ochoa-Gondar O, Rodriguez-Blanco T, Raga-Luria X, Gomez-Bertomeu F. Epidemiology of community-acquired pneumonia in older adults: a population-based study. *Respir Med* 2009; 103(2): 309-16. DOI: 10.1016/j.rmed.2008.08.006
8. Jokinen C, Heiskanen L, Juvonen H, Kallinen S, Karkola K, Korppi M, et al. Incidence of

- community-acquired pneumonia in the population of four municipalities in eastern Finland. *Am J Epidemiol* 1993; 137(9): 977-88. DOI: 10.1093/oxfordjournals.aje.a116770
9. File TM, Jr., Marrie TJ. Burden of community-acquired pneumonia in North American adults. *Postgrad Med* 2010; 122(2): 130-41. DOI: 10.3810/pgm.2010.03.2130
 10. Fry AM, Shay DK, Holman RC, Curns AT, Anderson LJ. Trends in hospitalizations for pneumonia among persons aged 65 years or older in the United States, 1988-2002. *JAMA* 2005; 294(21): 2712-9. DOI: 10.1001/jama.294.21.2712
 11. Varshochi M, Kianmehr P, Naghavi-Behzad M, Bayat-Makoo Z. Correspondence between hospital admission and the pneumonia severity index (PSI), CURB-65 criteria and comparison of their predictive value in mortality and hospital stay. *Infez Med* 2013; 21(2): 103-10.
 12. Koivula I, Sten M, Makela PH. Risk factors for pneumonia in the elderly. *Am J Med* 1994; 96(4): 313-20. DOI: 10.1016/0002-9343(94)90060-4
 13. Farr BM, Woodhead MA, Macfarlane JT, Bartlett CL, McCracken JS, Wadsworth J, et al. Risk factors for community-acquired pneumonia diagnosed by general practitioners in the community. *Respir Med* 2000; 94(5): 422-7. DOI: 10.1053/rmed.1999.0743
 14. Almirall J, Bolibar I, Balanzo X, Gonzalez CA. Risk factors for community-acquired pneumonia in adults: A population-based case-control study. *Eur Respir J* 1999; 13(2): 349-55. DOI: 10.1183/09031936.99.13234999
 15. Jackson ML, Neuzil KM, Thompson WW, Shay DK, Yu O, Hanson CA, et al. The burden of community-acquired pneumonia in seniors: Results of a population-based study. *Clin Infect Dis* 2004; 39(11): 1642-50. DOI: 10.1086/425615
 16. Musher DM, Roig IL, Cazares G, Stager CE, Logan N, Safar H. Can an etiologic agent be identified in adults who are hospitalized for community-acquired pneumonia: results of a one-year study. *J Infect* 2013; 67(1): 11-8. DOI: 10.1016/j.jinf.2013.03.003
 17. Zalacain R, Torres A, Celis R, Blanquer J, Aspa J, Esteban L, et al. Community-acquired pneumonia in the elderly: Spanish multicentre study. *Eur Respir J* 2003; 21(2): 294-302. DOI: 10.1183/09031936.03.00064102
 18. Fang GD, Fine M, Orloff J, Arisumi D, Yu VL, Kapoor W, et al. New and emerging etiologies for community-acquired pneumonia with implications for therapy. A prospective multicenter study of 359 cases. *Medicine (Baltimore)* 1990; 69(5): 307-16. DOI: 10.1097/00005792-199009000-00004
 19. Metlay JP, Schulz R, Li YH, Singer DE, Marrie TJ, Coley CM, et al. Influence of age on symptoms at presentation in patients with community-acquired pneumonia. *Arch Intern Med* 1997; 157(13): 1453-9. DOI: 10.1001/archinte.157.13.1453
 20. Johnstone J, Mandell L. Guidelines and quality measures: do they improve outcomes of patients with community-acquired pneumonia? *Infect Dis Clin North Am* 2013; 27(1): 71-86. DOI: 10.1016/j.idc.2012.11.001
 21. Mandell LA, Wunderink RG, Anzueto A, Bartlett JG, Campbell GD, Dean NC, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. *Clin Infect Dis* 2007; 44 Suppl 2: S27-S72. DOI: 10.1086/511159
 22. Heckerling PS, Tape TG, Wigton RS, Hissong KK, Leikin JB, Ornato JP, et al. Clinical prediction rule for pulmonary infiltrates. *Ann Intern Med* 1990; 113(9): 664-70.
 23. Emerman CL, Dawson N, Speroff T, Siciliano C, Effron D, Rashad F, et al. Comparison of physician judgment and decision aids for ordering chest radiographs for pneumonia in outpatients. *Ann Emerg Med* 1991; 20(11): 1215-9. DOI: 10.1016/S0196-0644(05)81474-X
 24. Sherman S, Skoney JA, Ravikrishnan KP. Routine chest radiographs in exacerbations of chronic obstructive pulmonary disease. Diagnostic value. *Arch Intern Med* 1989; 149(11): 2493-6.
 25. Syrjala H, Broas M, Suramo I, Ojala A, Lahde S. High-resolution computed tomography for the diagnosis of community-acquired pneumonia. *Clin Infect Dis* 1998; 27(2): 358-63. DOI: 10.1086/514675
 26. Baraff LJ. Management of fever without source in infants and children. *Ann Emerg Med* 2000; 36(6): 602-14. DOI: 10.1067/mem.2000.110820
 27. Bramson RT, Meyer TL, Silbiger ML, Blickman JG, Halpern E. The futility of the chest radiograph in the febrile infant without respiratory symptoms. *Pediatrics* 1993; 92(4): 524-6. DOI: 10.1016/S0196-0644(94)80407-9
 28. Moberley S, Holden J, Tatham DP, Andrews RM. Vaccines for preventing pneumococcal infection in adults. *Cochrane Database Syst Rev* 2013; (1): CD000422. DOI: 10.1002/14651858.CD000422.pub3
 29. Centers for Disease Control and Prevention (CDC). Vital signs: Current cigarette smoking among adults aged ≥ 18 years--United States, 2005-2010. *MMWR Morb Mortal Wkly Rep* 2011; 60(35): 1207-12.
 30. Sherwin RL, Gray S, Alexander R, McGovern PC, Graepel J, Pride MW, et al. Distribution of 13-valent pneumococcal conjugate vaccine *Streptococcus pneumoniae* serotypes in US adults aged ≥ 50 years with community-acquired pneumonia. *J Infect Dis* 2013; 208(11): 1813-20. DOI: 10.1093/infdis/jit506
 31. Longo DL, Fauci AS, Harrison TR, Kasper DL, Hauser SL, Jameson JL, et al. *Harrison's principles of internal medicine*. 18th ed. New York, NY: McGraw-Hill Medical; 2012.
 32. Baudouin SV. The pulmonary physician in critical care. 3: critical care management of community acquired pneumonia. *Thorax* 2002; 57(3): 267-71.

- DOI: 10.1136/thorax.57.3.267
- 33.** Fine MJ, Orloff JJ, Arisumi D, Fang GD, Arena VC, Hanusa BH, et al. Prognosis of patients hospitalized with community-acquired pneumonia. *Am J Med* 1990; 88(5N): 1N-8N.
- 34.** Lim WS, Macfarlane JT. Defining prognostic factors in the elderly with community acquired pneumonia: A case controlled study of patients aged > or = 75 yrs. *Eur Respir J* 2001; 17(2): 200-5.
- 35.** Weir DL, Majumdar SR, McAlister FA, Marrie TJ, Eurich DT. The impact of multimorbidity on short-term events in patients with community-acquired pneumonia: prospective cohort study. *Clin Microbiol Infect* 2015; 21(3): 264. DOI: 10.1016/j.cmi.2014.11.002
- 36.** Song JH, Oh WS, Kang CI, Chung DR, Peck KR, Ko KS, et al. Epidemiology and clinical outcomes of community-acquired pneumonia in adult patients in Asian countries: a prospective study by the Asian network for surveillance of resistant pathogens. *Int J Antimicrob Agents* 2008; 31(2): 107-14. DOI: 10.1016/j.ijantimicag.2007.09.014
- 37.** Welte T, Kohnlein T. Global and local epidemiology of community-acquired pneumonia: the experience of the CAPNETZ Network. *Semin Respir Crit Care Med* 2009; 30(2): 127-35. DOI: 10.1055/s-0029-1202941
- 38.** Fujiki R, Kawayama T, Ueyama T, Ichiki M, Aizawa H. The risk factors for mortality of community-acquired pneumonia in Japan. *J Infect Chemother* 2007; 13(3): 157-65. DOI: 10.1007/s10156-007-0512-0
- 39.** Garbino J, Sommer R, Gerber A, Regamey C, Vernazza P, Genne D, et al. Prospective epidemiologic survey of patients with community-acquired pneumonia requiring hospitalization in Switzerland. *Int J Infect Dis* 2002; 6(4): 288-93.